

Biocide tolerance and antibiotic resistance of *Enterobacter* spp. isolated from an Algerian hospital environment

Zakaria Boutarfi^a, Sid-Ahmed Rebiahi^a, Touhami Morghad^a, Ruben Perez Pulido^b, Maria Jose Grande Burgos^b, Fatima Mahdi^a, Rosario Lucas^b, Antonio Galvez^{a,*}

^a Laboratoire de Microbiologie Appliquée à l'Agroalimentaire, au Biomédical et à l'Environnement (LAMAABE), Université de Tlemcen, Tlemcen, Algeria

^b Department of Health Sciences, Microbiology Division, University of Jaén, 23071 Jaén, Spain

ARTICLE INFO

Article history:

Received 4 March 2019

Received in revised form 3 April 2019

Accepted 6 April 2019

Available online 18 April 2019

Keywords:

Enterobacter

Biocides

Antibiotics

Resistance

ABSTRACT

Objectives: In this study, 77 *Enterobacter* spp. isolates from a collection of 175 Gram-negative bacilli isolated from Tlemcen University Hospital Center (North-West of Algeria) were tested for antibiotic resistance, biocide tolerance and genetic determinants of antimicrobial resistance.

Methods: The isolates were identified by 16S rDNA gene sequencing. Biocide tolerance was determined by broth microdilution, and antibiotic resistance was determined by disk diffusion. Genetic determinants of resistance were studied by PCR amplification using suitable primers.

Results: The most common *Enterobacter* species was *Enterobacter cloacae* (58.4%), followed by *Enterobacter hormaechei* (24.7%). The most common antibiotic resistance was to ticarcillin either alone or in combination with clavulanic acid (70.1%), followed by cefepime (68.8%), cefotaxime (63.6%), ceftazidime (54.5%) and gentamicin (54.5%). Tobramycin was active against 87.0% of the isolates. Levels of biocide tolerance were high for hexachlorophene and to a lesser extent for benzalkonium chloride. The extended-spectrum β -lactamase genes *bla*_{TEM} and *bla*_{CTX-M} were detected in 44.2% and 36.4% of isolates, respectively. Other antimicrobial resistance genes (ARGs) frequently detected were *aac*(6')-Ib (57.1%) and *sul2* (50.6%). Multidrug-resistant isolates carrying several ARGs were common. Significant positive correlations were detected for efflux pump genes with ARGs and also between ARGs.

Conclusion: The results of this study reveal that *Enterobacter* spp. isolates from hospital settings are both resistant to clinically-used antibiotics and tolerant to biocides. Biocide tolerance could be an advantage for antibiotic-resistant strains in hospitals.

© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Nosocomial infections are responsible for significant morbidity and mortality in the hospital environment [1]. It has been estimated that 20–40% of healthcare-related infections are due to cross-transmission via the hands of caregivers contaminated by direct contact with patients or indirectly by touching contaminated environmental surfaces [2]. In recent years, considerable efforts have been made to improve control practices for these infections, which has led to increased use of biocides [3]. The latter can often lead to the appearance of the adaptation phenomenon and consequently to resistance to biocide molecules [4], which

regularly affects new species [5,6]. Although bacterial insensitivity to biocides was described in the 1950s and 1960s and appears to be increasing [7], debate is currently ongoing regarding the possible emergence of biocide tolerance in hospitals and whether this tolerance may be accompanied by antibiotic resistance. Although few studies have confirmed this co-resistance [8,9], some authors have reported that Gram-negative bacteria that have developed tolerance to certain biocidal compounds may also be non-susceptible to certain antibiotics [10].

Enterobacter spp. are frequently found in natural environments such as water, wastewater, vegetables and soil [11]. These bacteria are a very common pathogen and are frequently isolated in hospitals [12,13]. They are therefore often involved in healthcare-related infections, causing 8% of nosocomial bacteraemia cases, and are also the second most common Gram-negative pathogen of pneumonia in intensive care unit patients [14]. The presence of *Enterobacter* spp. in hospital settings is increasingly alarming because of its rapid development of antimicrobial resistance [11].

* Corresponding author. Present address: Área de Microbiología, Departamento de Ciencias de la Salud, Facultad de Ciencias Experimentales, Edif. B3, Universidad de Jaén, Campus Las Lagunillas s/n, 23071 Jaén, Spain.

E-mail address: agalvez@ujaen.es (A. Galvez).

Some species belonging to this genus are capable of acquiring many mechanisms that contribute significantly to antimicrobial resistance, which considerably reduces therapeutic choices [14,15].

Since no report regarding the status of biocide tolerance in Algeria is available, the aim of the current study was to determine the efficacy of biocides on a collection of *Enterobacter* spp. isolates of hospital origin and to explore the possible correlation between tolerance to biocides and antibiotic resistance as well as to characterise the genetic background of this antimicrobial resistance.

2. Materials and methods

2.1. Sampling and bacterial isolation

A total of 256 samples were obtained over 5 months (November 2015 to March 2016) in the operating theatres of the targeted services (surgery A, orthopaedics and traumatology, and medical-surgical emergencies) at Tlemcen University Hospital Center (North-West of Algeria). The samples were taken by the swabbing technique on different surfaces. Following enrichment in brain-heart infusion broth (Liofilchem, Roseto degli Abruzzi, Italy) for 24 h at 37 °C, bacteria were isolated and purified on MacConkey agar (Liofilchem).

2.2. Identification of bacterial isolates

Isolates were first identified by conventional tests (Gram stain, catalase test and oxidase test) and were confirmed using an API 20E system (bioMérieux, Marcy-l'Étoile, France). For molecular identification, amplification of the 16S rDNA gene was performed as previously described [16,17]. Following DNA extraction using a Bacterial Genomic DNA Extraction Kit (Xtrem Biotech, SL, Granada, Spain) according to the manufacturer's instructions, amplicons were purified using an Illustra™ ExoProStar 1-step Purification Kit (GE Healthcare, Little Chalfont, UK) and were then sequenced by the sequencing centre Sistemas Genómicos (Valencia, Spain). A search for homology of the DNA sequences was performed using the BLAST algorithm available at the National Center for Biotechnology Information (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

2.3. Antimicrobial susceptibility testing

Isolates identified as *Enterobacter* spp. were selected for further study. The susceptibility of *Enterobacter* spp. isolates to the antibiotics ticarcillin, ticarcillin/clavulanic acid, piperacillin/tazobactam, ceftazidime, cefotaxime, cefepime, imipenem, trimethoprim/sulfamethoxazole, chloramphenicol, ciprofloxacin, ofloxacin, amikacin, gentamicin, fosfomicin, nalidixic acid, tobramycin, colistin and aztreonam was tested by the disk diffusion method on Mueller–Hinton agar (Liofilchem) according to Clinical and Laboratory Standards Institute (CLSI) guidelines [18].

2.4. Determination of biocide tolerance

Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method for the following five biocides: benzalkonium chloride (BC); cetrimide; chlorhexidine; hexadecylpyridinium chloride; and hexachlorophene (CF). CF was dissolved in ethanol (10% w/v). The remaining biocides were aseptically dissolved in tryptic soy broth (Liofilchem) to achieve final concentrations ranging from 8–2048 mg/L. Then, 180 µL of each biocide dilution was incubated with a bacterial suspension adjusted to a density equivalent to 5×10^5 CFU/mL.

Positive controls (broth + bacterial suspension) and negative controls (broth + biocide) were included in the microplate. Incubation was performed for 24 h at 37 °C and the optical density

reading was carried out using a ELx808 microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).

2.5. Detection of antimicrobial resistance genes (ARGs) by PCR

Genes related to antimicrobial resistance were investigated by PCR using the primers indicated in Supplementary Table S1. The efflux pump genes searched for were *mdfA* [19] and *oqxA* of the OqxAB multidrug efflux pump [20].

The investigated genes encoding β-lactam resistance were *bla*_{TEM} [21], *bla*_{PSE} [22], *bla*_{CTX-M} and *bla*_{CTX-M-2} [23], *bla*_{NDM-1}, *bla*_{IMP}, *bla*_{OXA-23} and *bla*_{VIM-2} [24]. Other genetic determinants investigated were as follows: the tetracycline resistance genes *tet*(B), *tet*(C) and *tet*(D) [25]; the aminoglycoside resistance gene *aac*(6')-Ib [26]; the streptomycin resistance gene *aadA* [27]; the phenicol resistance gene *floR* [22]; the trimethoprim resistance genes *dfrA12* and *dfrA15* [27]; and the sulfonamide resistance genes *sul1*, *sul2* and *sul3* [21]. The integrase gene *intI1* was investigated using the primers *intF* and *intR* [28].

2.6. Statistical analysis

Statistical analysis, including the correlation matrix, was performed using IBM SPSS Statistics for Windows v.22 (IBM Corp., Armonk, NY). Positive correlations were defined as very weak (0.00–0.19), weak (0.20–0.39), moderate (0.40–0.59), strong (0.60–0.79) or very strong (0.80–0.99), with significant *P*-values of <0.05.

3. Results

3.1. Bacterial identification

A total of 175 Gram-negative bacilli were recovered from the hospital samples. 16S rDNA gene sequencing allowed the identification of 77 *Enterobacter* spp. isolates, representing a prevalence of 44.0%. *Enterobacter cloacae* was the most common species (45/77; 58.4%), followed by *Enterobacter hormaechei* (19/77; 24.7%). Other species identified were *Enterobacter xiangfangensis* (4/77; 5.2%), *Enterobacter cancerogenus* (1/77; 1.3%) and *Enterobacter (Cronobacter) sakazakii* (1/77; 1.3%).

3.2. Antimicrobial susceptibility

Among the β-lactams tested, imipenem was the most efficient, with only six resistant isolates. Some β-lactam antibiotics were not effective, e.g. a resistance rate of approximately 70% for ticarcillin; combination of ticarcillin with clavulanic acid did not significantly restore its effectiveness. The tested cephalosporins (cefepime, cefotaxime and ceftazidime) and monobactams (aztreonam) were moderately effective, with resistance rates of 68.8%, 63.6%, 54.5% and 41.6%, respectively. The activity of quinolones differed depending on the molecule used, with recorded resistance rates of 46.8% for nalidixic acid, 20.8% for ciprofloxacin and 11.7% for ofloxacin. Aminoglycosides were not spared of the resistance phenomenon, although tobramycin was active against 87.0% of the isolates. Gentamicin was ineffective against 54.5% of the isolates. It should be noted that no colistin-resistant isolates were identified during the study.

3.3. Biocide tolerance

The MICs of the five biocides are shown in Table 1. MIC distributions for the predominant species found in the study (*E. cloacae* and *E. hormaechei*) are shown in Fig. 1. The activity of the biocides differed according to the molecules tested. Thus, some biocides were distinguished by high MICs (up to 128 mg/L for CF),

Table 1
Antibiotic resistance, biocide tolerance and genetic determinants of resistance detected in *Enterobacter* spp. isolates from an Algerian hospital environment (n = 77).

<i>Enterobacter</i> spp. ^a	Detected ARG(s)	Antibiotic resistance ^b	Biocide MIC (mg/L)				
			HDP	BC	CF	CT	CH
<i>E. cancerogenus</i> zb01	<i>aac(6')-Ib</i>	TIC, TCC, CTX, FEP, CIP	32	32	64	64	32
<i>E. cloacae</i> zb01	<i>aac(6')-Ib, dfrA12, sul2, bla_{TEM}, bla_{VIM-2}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, IPM, SXT, CHL, CIP, OFX, AMK, GEN, NAL	32	64	128	32	16
<i>E. cloacae</i> zb02	<i>dfrA12, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, CIP, GEN, NAL	32	32	128	64	8
<i>E. cloacae</i> zb03	<i>aac(6')-Ib, sul2, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN, ATM	32	32	128	32	8
<i>E. cloacae</i> zb04	<i>intI1</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, CIP, OFX, AMK, GEN, NAL, TOB, ATM	64	32	128	64	16
<i>E. cloacae</i> zb05	<i>dfrA12</i>	FOS	64	32	128	64	16
<i>E. cloacae</i> zb06		CTX	64	32	128	32	32
<i>E. cloacae</i> zb07	<i>sul2, tet(B), floR, bla_{NDM-1}, bla_{OXA-23}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, IPM, SXT, CHL, CIP, OFX, AMK, GEN, NAL, TOB, ATM	64	64	128	32	16
<i>E. cloacae</i> zb08	<i>aac(6')-Ib, dfrA12, sul2, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, TOB, ATM	64	64	128	64	32
<i>E. cloacae</i> zb09	<i>aac(6')-Ib, intI1</i>	TIC, CHL	32	64	128	64	8
<i>E. cloacae</i> zb10	<i>dfrA12, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{CTX-M-2}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, GEN, NAL, ATM	32	64	128	64	16
<i>E. cloacae</i> zb11	<i>dfrA12, sul1, aac(6')-Ib</i>	TIC, TCC, CHL, ATM	64	64	128	32	32
<i>E. cloacae</i> zb12	<i>dfrA12, mdfA, sul2, tet(B), aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN, ATM	16	32	64	32	32
<i>E. cloacae</i> zb13	<i>dfrA12, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{CTX-M-2}, bla_{TEM}</i>	TIC, TCC, TZP, FEP	64	32	128	32	16
<i>E. cloacae</i> zb14	<i>dfrA12</i>		32	32	128	32	32
<i>E. cloacae</i> zb15	<i>intI1, bla_{CTX-M-2}</i>	ATM	16	32	128	64	32
<i>E. cloacae</i> zb16	<i>sul2, aadA, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	128	16	64	32	32
<i>E. cloacae</i> zb17	<i>sul2, aac(6')-Ib, bla_{CTX-M}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, IPM, SXT, CHL, CIP, OFX, AMK, GEN, NAL, TOB, ATM	32	32	128	64	32
<i>E. cloacae</i> zb18	<i>oqxA, floR</i>	FEP, FOS	<512	64	64	64	32
<i>E. cloacae</i> zb19	<i>aadA, aac(6')-Ib</i>	FEP	64	32	128	32	32
<i>E. cloacae</i> zb20	<i>dfrA12, aac(6')-Ib</i>		64	32	64	32	32
<i>E. cloacae</i> zb21	<i>intI1, aac(6')-Ib, floR</i>	TZP, CTX, FEP	<512	64	64	64	32
<i>E. cloacae</i> zb22	<i>bla_{CTX-M}, bla_{IMP}</i>	TIC, TCC, CAZ, CTX, FEP, IPM, GEN, ATM	<512	128	64	128	64
<i>E. cloacae</i> zb23	<i>sul1, sul2, aadA, bla_{IMP}</i>	TIC, TCC, CAZ, CTX, FEP, IPM, SXT, CHL, GEN, NAL, ATM	32	128	128	64	32
<i>E. cloacae</i> zb24	<i>dfrA12, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	64	32	64	32	16
<i>E. cloacae</i> zb25	<i>dfrA12, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, CIP, GEN, NAL	64	32	128	32	16
<i>E. cloacae</i> zb26	<i>bla_{CTX-M}</i>	FOS	64	32	128	64	16
<i>E. cloacae</i> zb27	<i>floR</i>	TIC, TCC, CAZ	8	8	128	32	4
<i>E. cloacae</i> zb28	<i>dfrA12, aadA, aac(6')-Ib</i>	TIC, TCC, FEP, SXT, CHL, OFX, NAL	64	32	128	32	16
<i>E. cloacae</i> zb29	<i>dfrA12, aac(6')-Ib</i>	TIC, TCC, CTX, FEP, SXT, CHL, CIP, OFX, NAL	64	32	128	32	16
<i>E. cloacae</i> zb30	<i>intI1, sul2</i>	TIC, TCC, CAZ, CTX, FEP, AMK, GEN, ATM	32	32	64	64	32
<i>E. cloacae</i> zb31	<i>sul2, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN	64	64	128	32	32
<i>E. cloacae</i> zb32	<i>aac(6')-Ib</i>	CHL, ATM	64	32	128	32	32
<i>E. cloacae</i> zb33	<i>aac(6')-Ib, bla_{CTX-M}</i>	TIC, TCC, CAZ, CTX, SXT, AMK, GEN, NAL, TOB, ATM	32	32	128	32	32
<i>E. cloacae</i> zb34	<i>dfrA12, oqxA, sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, CIP, GEN, NAL	64	64	128	32	32
<i>E. cloacae</i> zb35	<i>dfrA12, aadA, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL	32	32	128	16	32
<i>E. cloacae</i> zb36	<i>bla_{CTX-M}</i>		256	64	128	32	8
<i>E. cloacae</i> zb37	<i>sul1, aadA, aac(6')-Ib</i>	CTX, CHL, NAL	32	16	128	32	32
<i>E. cloacae</i> zb38	<i>sul1, aadA</i>	TIC, CTX, FEP, CHL, AMK, GEN, FOS	32	32	128	32	32
<i>E. cloacae</i> zb39	<i>dfrA12, sul2, aadA, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL	32	32	128	32	32
<i>E. cloacae</i> zb40	<i>dfrA12, bla_{CTX-M}</i>		32	32	64	64	32
<i>E. cloacae</i> zb41	<i>dfrA12, sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	64	32	128	32	16
<i>E. cloacae</i> zb42	<i>intI1, sul2, aac(6')-Ib, bla_{CTX-M}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	32	32	128	64	32
<i>E. cloacae</i> zb43	<i>sul1, sul2, sul3, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, CIP, OFX, AMK, GEN, NAL, TOB, ATM	32	32	128	32	32
<i>E. cloacae</i> zb44	<i>intI1, sul2</i>		64	32	128	64	32
<i>E. cloacae</i> zb45	<i>intI1, dfrA12, sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, CIP, GEN, NAL	64	32	128	32	32
<i>E. hormaechei</i> zb01	<i>intI1, sul2, aadA, floR, bla_{TEM}</i>		32	32	128	32	16
<i>E. hormaechei</i> zb02	<i>dfrA12, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, AMK, GEN, NAL	8	32	128	32	32
<i>E. hormaechei</i> zb03			64	32	128	64	64
<i>E. hormaechei</i> zb04		TIC, TCC, FEP	64	32	64	32	32
<i>E. hormaechei</i> zb05	<i>intI1, sul1</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN	32	64	64	64	32
<i>E. hormaechei</i> zb06	<i>tet(D)</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CIP, OFX, AMK, GEN, NAL, TOB, ATM	64	64	128	32	16
<i>E. hormaechei</i> zb07	<i>sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	128	32	128	32	32
<i>E. hormaechei</i> zb08	<i>sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, CHL, CIP, GEN, TOB, ATM	128	16	64	32	32
<i>E. hormaechei</i> zb09	<i>sul2, aac(6')-Ib, bla_{CTX-M}</i>	TIC, TCC, CAZ, CTX, FEP, AMK, GEN, ATM	32	32	128	64	32
<i>E. hormaechei</i> zb10	<i>dfrA12, sul2, aadA, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, GEN, NAL, ATM	128	64	128	64	64
<i>E. hormaechei</i> zb11	<i>sul1, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, CIP, AMK, GEN, NAL, ATM	32	32	128	32	32
<i>E. hormaechei</i> zb12	<i>dfrA12, sul2, aac(6')-Ib, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, TOB, ATM	64	32	128	32	32
<i>E. hormaechei</i> zb13		TIC, TCC, FEP, AMK	64	32	64	64	32
<i>E. hormaechei</i> zb14	<i>dfrA12</i>		32	16	128	64	16
<i>E. hormaechei</i> zb15	<i>sul2, aac(6')-Ib, bla_{TEM}</i>	FEP	128	32	128	64	32
<i>E. hormaechei</i> zb16	<i>intI1, sul2, aac(6')-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	64	64	128	32	32
<i>E. hormaechei</i> zb17	<i>sul2</i>		32	32	64	64	16

Table 1 (Continued)

Enterobacter spp. ^a	Detected ARG(s)	Antibiotic resistance ^b	Biocide MIC (mg/L)				
			HDP	BC	CF	CT	CH
<i>E. hormaechei</i> zb18	<i>dfrA12, sul2, aadA, aac(6′)-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CHL, AMK, GEN, NAL, ATM	64	32	128	32	16
<i>E. hormaechei</i> zb19	<i>int1, dfrA12, sul2, aadA, aac(6′)-Ib, bla_{TEM}, bla_{IMP}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL, ATM	32	64	64	64	32
<i>E. (Cronobacter) sakazakii</i> zb01	<i>mdfA, sul2, tet(B), aac(6′)-Ib, floR</i>	TIC, TCC, CAZ, CTX, FEP, SXT, CIP, OFX, AMK, GEN, NAL, TOB, ATM	32	64	128	32	32
<i>Enterobacter</i> sp. zb01	<i>oqxA, aac(6′)-Ib, floR, bla_{TEM}</i>	FOS	<512	64	128	64	32
<i>Enterobacter</i> sp. zb02	<i>aadA, bla_{TEM}</i>		128	32	128	64	32
<i>Enterobacter</i> sp. zb03	<i>mdfA, tet(B), aadA, floR</i>	TIC, TCC, TZP, FEP, CHL, NAL	32	32	128	32	4
<i>Enterobacter</i> sp. zb04	<i>dfrA12, sul2, aac(6′)-Ib, bla_{TEM}</i>	TIC, TCC, TZP, CAZ, CTX, FEP, SXT, CHL, GEN, NAL	64	32	64	32	16
<i>Enterobacter</i> sp. zb05	<i>dfrA12, sul2, aac(6′)-Ib, bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CAZ, CTX	16	32	128	32	32
<i>Enterobacter</i> sp. zb06		TZP, FEP, FOS	64	32	128	32	16
<i>Enterobacter</i> sp. zb07	<i>dfrA12, sul1, bla_{CTX-M-2}</i>	TIC, TCC, CAZ, CTX, FEP, CIP, GEN, NAL	32	32	128	64	16
<i>E. xiangfangensis</i> zb01	<i>dfrA12, sul2, bla_{CTX-M}</i>	TIC, TCC, TZP, CTX, FEP, SXT, CHL, GEN, NAL, ATM	64	32	128	64	32
<i>E. xiangfangensis</i> zb02	<i>mdfA, sul1, sul2, tet(B), bla_{CTX-M}, bla_{TEM}</i>	TIC, TCC, CTX, CHL	64	64	128	32	32
<i>E. xiangfangensis</i> zb03	<i>aac(6′)-Ib</i>		32	32	128	64	8
<i>E. xiangfangensis</i> zb04	<i>int1, mdfA, sul2, tet(B), aadA, aac(6′)-Ib, bla_{CTX-M}, bla_{TEM}, bla_{OXA-23}</i>	TIC, TCC, CAZ, CTX, FEP, IPM, GEN, ATM	64	32	128	64	32

ARG, antimicrobial resistance gene; MIC, minimum inhibitory concentration; HDP, hexadecylpyridinium chloride; BC, benzalkonium chloride; CF, hexachlorophene; CT, cetrimeride; CH, chlorhexidine.

^a Isolates were identified by 16S rDNA gene sequencing.

^b AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CHL, chloramphenicol; CIP, ciprofloxacin; CTX, cefotaxime; FEP, cefepime; FOS, fosfomycin; GEN, gentamicin; IPM, imipenem; NAL, nalidixic acid; OFX, ofloxacin; SXT, trimethoprim/sulfamethoxazole; TCC, ticarcillin/clavulanic acid; TIC, ticarcillin; TOB, tobramycin; TZP, piperacillin/tazobactam.

reflecting both a possible tolerance of the *Enterobacter* isolates tested and a probable inefficiency of this type of product. Strains with high MICs for BC of 64 mg/L (24.7%) or 128 mg/L (2.6%) were also detected. Otherwise, molecules such as chlorhexidine were characterised by moderate MICs reaching 32 mg/L for 61% of isolates.

Results of biocide tolerance also revealed a strain-dependent effect in which some isolates were found to be tolerant to several antibiotics, reflecting a possible accumulation of resistance mechanisms.

3.4. Genetic determinants of resistance

Results of PCR amplification of genes encoding efflux pumps revealed the presence of the *mdfA* gene in 6.5% of isolates (5/77) (Table 1) and the *oqxA* gene in 3.9% (3/77).

Regarding resistance to β -lactams, the extended-spectrum β -lactamase (ESBL) genes *bla_{TEM}*, *bla_{CTX-M}* and *bla_{CTX-M-2}* were detected in 44.2% (33/77), 36.4% (28/77) and 5.2% (4/77) of the isolates, respectively, and only two isolates carried these three genes together. The *bla_{PSE}* gene was not detected in any of the tested isolates.

The presence of genes responsible for the production of metallo- β -lactamases (MBLs) was also observed. The *bla_{VIM-2}* and *bla_{NDM-1}* genes were found in one isolate (1.3%) each, whereas this percentage was higher for *bla_{IMP}* (3/77; 3.9%) and *bla_{OXA-23}* (2/77; 2.6%).

The tetracycline resistance genes *tet(B)* and *tet(D)* were found with frequencies of 7.8% (6/77) and 1.3% (1/77), respectively, however the *tet(C)* gene was not detected. Unlike the *sul1* and *sul3* genes that were present with lower frequencies [11.7% (9/77) and 1.3% (1/77), respectively], 50.6% of isolates (39/77) carried the *sul2* gene. The integrase gene *int1* of class 1 integrons associated with sulfonamide resistance genes was detected in 16.9% of isolates (13/77).

The *aac(6′)-Ib* gene involved in aminoglycoside resistance was the most predominant (57.1% of isolates; 44/77). The *aadA* gene responsible of streptomycin resistance was found in 28.6% of isolates (22/77), whilst the gene *floR* encoding resistance to phenicols was found in 10.4% (8/77). It is also worth noting that

many isolates carried several ARGs, with up to eight ARGs in one strain (Table 1).

3.5. Correlation between the presence of different antimicrobial resistance genes

The efflux pump gene *oqxA* showed a weak (significant) positive correlation only with *floR* (Table 2), whilst the *mdfA* gene showed weak positive correlations with *floR* and *bla_{OXA-23}* and also a very strong positive correlation with the *tet(B)* tetracycline resistance gene. The *tet(B)* gene also showed significant positive correlations with *bla_{OXA-23}* and *bla_{NDM-1}*. Strong positive correlations were detected for the β -lactamase gene *bla_{OXA-23}* with *bla_{NDM-1}* and for *bla_{TEM}* with *sul2*. The *aac(6′)-Ib* gene showed moderate or weak positive correlations with *bla_{TEM}*, *bla_{CTX-M}*, *dfrA12* and *sul2*.

Moreover, the correlation was negative between some of the studied ARGs, particularly between *floR* and *dfrA12* and between *sul1* and *bla_{CTX-M}*.

4. Discussion

The presence of *Enterobacter* spp. in the hospital environment is alarming because it can cause serious infections especially when it accumulates antimicrobial resistance mechanisms [15]. In contrast to antibiotics, there is no consensus on the standardisation of susceptibility to biocides [29].

The results of the present study suggest that a large percentage of *Enterobacter* spp. isolates tolerate high concentrations of biocides, specifically CF (up to 128 mg/L) and BC (64 mg/L or 128 mg/L). These results appear to disagree with those reported by Morrissey et al. [29] who estimated a MIC of 16 mg/L for BC and those of Fernández Fuentes et al. [30] who report MICs in the range of 10–100 mg/L for CF. This discrepancy could be the result of several factors, such as the selection pressure of biocide-tolerant mutants or modification of membrane rigidity [31].

Repeated exposure of a microbial community to biocides not only increases the selection of biocide-resistant bacteria but may also contribute to the expression and spread of antibiotic resistance mechanisms [31]. This phenomenon could be explained by the similarity of the resistance mechanisms [32]. Although most




Fig. 1. Distribution of minimum inhibitory concentrations (MICs) for five different biocides against (A) *Enterobacter cloacae* and (B) *Enterobacter hormaechei* isolates from an Algerian hospital environment. BC, benzalkonium chloride; CT, cetrimide; CH, chlorhexidine; HDP, hexadecylpyridinium chloride; CF, hexachlorophene.

antibiotic resistance mechanisms are specific and result in resistance to a single molecule or class of antimicrobials, there are currently many examples of efflux systems that contribute to resistance to a wide range of structurally independent antimicrobials, including antibiotics and biocides [32].

Many of the isolates with high-level tolerance to CF were also multiply resistant to antibiotics, including fluoroquinolones such as ciprofloxacin and ofloxacin. This phenomenon of co-resistance was explained by Buffet-Bataillon et al. [33] who believe that the effects of non-antibiotic antimicrobials (quaternary ammonium compounds) have been so far underestimated, whilst various common mechanisms (including overexpression of efflux pumps, biofilm formation and spontaneous mutations) may contribute to

co-resistance between antibiotic and biocides. These data can be extrapolated to other antimicrobial agents.

In addition, the current results also indicate a possible negative correlation between tolerance to certain biocides and resistance to certain antibiotics, which could be an excellent alternative in the choice of molecules adapted to our context.

The results showed a possible correlation between ARGs, thus the presence of the *aac(6′)-Ib* gene accompanied that of *bla*_{CTX-M} and *bla*_{TEM}. This same association has been described in Algeria for the first time in a strain of ESBL-producing *E. cloacae* harbouring both *bla*_{CTX-M} and *bla*_{TEM} genes [34]. This coexistence is not always obvious, because in another study in Algeria the *aac(6′)-Ib* gene was not found [35].

Table 2
Correlations between the detected antimicrobial resistance genes.

	<i>aac(6)-Ib</i>	<i>aacA</i>	<i>bla_{CTX-M}</i>	<i>bla_{CTX-M-2}</i>	<i>bla_{IMP}</i>	<i>bla_{NDM-1}</i>	<i>bla_{OXA-23}</i>	<i>bla_{TEM}</i>	<i>bla_{VIM-2}</i>	<i>floR</i>	<i>tet(B)</i>	<i>tet(D)</i>	<i>dfrA12</i>	<i>mdfA</i>	<i>oqxA</i>	<i>sulI</i>	<i>sul2</i>	<i>sul3</i>	<i>intI1</i>
<i>aac(6)-Ib</i>	1																		
<i>aacA</i>	0.147	1																	
<i>bla_{CTX-M}</i>	0.288*	0.234*	1																
<i>bla_{CTX-M-2}</i>	-0.040	0.103	0.073	1															
<i>bla_{IMP}</i>	-0.103	0.162	-0.007	-0.047	1														
<i>bla_{NDM-1}</i>	-0.136	-0.075	-0.084	-0.027	-0.023	1													
<i>bla_{OXA-23}</i>	-0.028	0.072	0.051	-0.038	-0.033	0.702**	1												
<i>bla_{TEM}</i>	0.485**	0.391**	0.333**	0.028	-0.044	-0.102	0.019	1											
<i>bla_{VIM-2}</i>	0.097	-0.075	-0.084	-0.027	-0.023	-0.013	-0.019	0.129	1										
<i>floR</i>	-0.145	-0.036	0.250*	-0.080	-0.069	0.337**	0.212	-0.131	-0.039	1									
<i>tet(B)</i>	-0.050	0.128	-0.011	-0.068	-0.059	0.395**	0.034	0.034	0.377**	-0.033	1								
<i>tet(D)</i>	-0.136	-0.075	-0.084	-0.027	-0.023	-0.013	-0.019	-0.102	-0.039	-0.133	-0.033	1							
<i>dfrA12</i>	0.295**	0.119	0.194	0.173	-0.023	-0.092	-0.130	0.362**	0.144	0.272*	-0.102	1							
<i>mdfA</i>	0.008	0.173	0.027	-0.062	-0.053	-0.030	0.288*	0.084	-0.030	0.907**	-0.030	-0.102	1						
<i>oqxA</i>	0.034	0.015	-0.007	-0.047	-0.041	-0.023	-0.033	0.091	-0.023	-0.059	-0.023	-0.023	-0.053	1					
<i>sulI</i>	-0.185	0.116	0.267*	0.097	0.136	-0.042	-0.059	-0.079	-0.042	0.045	-0.042	-0.125	0.068	0.155	1				
<i>sul2</i>	0.380**	0.133	0.290*	-0.027	0.065	0.113	0.161	0.616**	0.113	-0.090	0.190	0.149	0.155	-0.070	-0.045	1			
<i>sul3</i>	-0.136	-0.075	-0.084	-0.027	-0.023	-0.013	-0.019	0.129	-0.013	-0.039	-0.033	-0.092	-0.030	-0.023	0.315**	0.113	1		
<i>intI1</i>	-0.042	0.009	-0.041	0.051	0.088	-0.052	0.144	-0.052	0.074	0.074	-0.002	-0.052	-0.218	0.022	-0.091	0.098	-0.052	1	

** Correlations were statistically significant at * $P < 0.05$ or ** $P < 0.001$.

Among the resistance genes investigated in this work, the *mdfA* gene was found in five isolates. Although this gene has been widely reported in *Escherichia coli* [36,37], other authors did not find it in *Enterobacter* spp. [38].

5. Conclusions

This work reveals worrisome tolerance to biocides in *Enterobacter* spp. isolates from an Algerian hospital environment. Biocide tolerance might be one of the factors for the co-selection of antibiotic resistance and the persistence of antibiotic-resistant strains in hospital settings. The results underline the needs to establish new strategies and to explore other alternatives against antibiotic-resistant bacteria, including new formulations or the use of bacteriophages, to fight these bacteria on surfaces before they can reach patients.

Funding

This work was supported by grant Estructura GrupoAGR230.

Competing interests

None declared.

Ethical approval

Not required.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.jgar.2019.04.005>.

References

- [1] Smith K, Hunter IS. Efficacy of common hospital biocides with biofilms of multi-drug resistant clinical isolates. J Med Microbiol 2008;57:966–73.
- [2] Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. Role of hospital surfaces in the transmission of emerging health care-associated pathogens: norovirus, *Clostridium difficile*, and *Acinetobacter* species. Am J Infect Control 2010;38:25–33.
- [3] Smith K, Gemmell CG, Hunter IS. The association between biocide tolerance and the presence or absence of *qac* genes among hospital-acquired and community-acquired MRSA isolates. J Antimicrob Chemother 2008;61:78–84.
- [4] Meyer B. Does microbial resistance to biocides create a hazard to food hygiene? Int J Food Microbiol 2006;112:275–9.
- [5] Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010;74:417–33.
- [6] Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock V LJ. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 2015;13:42–51.
- [7] Russell ADD. Mechanisms of bacterial resistance to biocides. Int Biodeterior Biodegradation 1995;36:247–65.
- [8] Wand ME, Bock LJ, Bonney LC, Sutton JM. Mechanisms of increased resistance to chlorhexidine and cross-resistance to colistin following exposure of *Klebsiella pneumoniae* clinical isolates to chlorhexidine. Antimicrob Agents Chemother 2017;61:e01162–16.
- [9] Webber MA, Whitehead RN, Mount M, Loman NJ, Pallen MJ, Piddock LJ. Parallel evolutionary pathways to antibiotic resistance selected by biocide exposure. J Antimicrob Chemother 2015;70:2241–8.
- [10] Russell AD. Do biocides select for antibiotic resistance? J Pharm Pharmacol 2000;52:227–33.
- [11] Forsythe SJ, Abbott SL, Pitout J, et al. *Klebsiella*, *Enterobacter*, *Citrobacter*, *Cronobacter*, *Serratia*, *Plesiomonas*, and other Enterobacteriaceae. 11th ed. In: Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, editors. Manual of clinical microbiology, vol. 1. Washington, DC: ASM Press; 2015. p. 714–31.
- [12] Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical–surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000;21:510–5.
- [13] Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016;35:1679–89.
- [14] Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant *Enterobacter* species: emergence of KPC-2 carbapene-

- mase, molecular characterization, epidemiology, and outcomes. *Antimicrob Agents Chemother* 2008;52:1413–8.
- [15] Davin-Regli A, Pagès JM. *Enterobacter aerogenes* and *Enterobacter cloacae*: versatile bacterial pathogens confronting antibiotic treatment. *Front Microbiol* 2015;6:392.
- [16] Abriouel H, Lucas R, Ben Omar N, Valdivia E, Maqueda M, Martínez-Cañamero M, et al. Enterocin AS-48RJ: a variant of enterocin AS-48 chromosomally encoded by *Enterococcus faecium* RJ16 isolated from food. *Syst Appl Microbiol* 2005;28:383–97.
- [17] Weisburg WG, Barns SM, Pelletier DA, Lane DJ. 16S ribosomal DNA amplification for phylogenetic study. *J Bacteriol* 1991;173:697–703.
- [18] Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S24. Wayne, PA: CLSI; 2014.
- [19] Swick MC, Morgan-Linnell SK, Carlson KM, Zechiedrich L. Expression of multidrug efflux pump genes *acrAB-tolC*, *mdfA*, and *norE* in *Escherichia coli* clinical isolates as a function of fluoroquinolone and multidrug resistance. *Antimicrob Agents Chemother* 2011;55:921–4.
- [20] Hansen LH, Sørensen SJ, Jørgensen HS, Jensen LB. The prevalence of the OqxAB multidrug efflux pump amongst olaquinox-resistant *Escherichia coli* in pigs. *Microb Drug Resist* 2005;11:378–82.
- [21] Saenz Y, Brinas L, Dominguez E, Ruiz J, Zarazaga M, Vila J, et al. Mechanisms of resistance in multiple-antibiotic-resistant *Escherichia coli* strains of human, animal, and food origins. *Antimicrob Agents Chemother* 2004;48:3996–4001.
- [22] Chiu CH, Su LH, Chu CH, Wang MH, Yeh CM, Weill FX, et al. Detection of multidrug-resistant *Salmonella enterica* serovar Typhimurium phage types DT102, DT104, and U302 by multiplex PCR. *J Clin Microbiol* 2006;44:2354–8.
- [23] Bertrand S, Weill FX, Cloeckaert A, Vrints M, Mairiaux E, Fraud K, et al. Clonal emergence of extended-spectrum β -lactamase (CTX-M-2)-producing *Salmonella enterica* serovar Virchow isolates with reduced susceptibilities to ciprofloxacin among poultry and humans in Belgium and France (2000 to 2003). *J Clin Microbiol* 2006;44:2897–903.
- [24] Ramakrishnan K, Rajagopalan S, Nair S, Kenchappa P, Chandrakesan SD. Molecular characterization of metallo β -lactamase producing multidrug resistant *Pseudomonas aeruginosa* from various clinical samples. *Indian J Pathol Microbiol* 2014;57:579–82.
- [25] Ng L-K, Martin I, Alfa M, Mulvey M. Multiplex PCR for the detection of tetracycline resistant genes. *Mol Cell Probes* 2001;15:209–15.
- [26] Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of *aac(6)-Ib-cr* encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* 2006;50:3953–5.
- [27] Guerra B, Soto SM, Argüelles JM, Mendoza MC. Multidrug resistance is mediated by large plasmids carrying a class 1 integron in the emergent *Salmonella enterica* serotype [4,5,12:i:-]. *Antimicrob Agents Chemother* 2001;45:1305–8.
- [28] Chuanchuen R, Khemtong S, Padungtod P. Occurrence of *qacE/qacE Δ 1* genes and their correlation with class 1 integrons in *Salmonella enterica* isolates from poultry and swine. *Southeast Asian J Trop Med Public Health* 2007;38:855–62.
- [29] Morrissey I, Oggioni MR, Knight D, Curiao T, Coque T, Kalkanci A, et al. Evaluation of epidemiological cut-off values indicates that biocide resistant subpopulations are uncommon in natural isolates of clinically-relevant microorganisms. *PLoS One* 2014;9:e86669.
- [30] Fernández Fuentes MÁ, Ortega Morente E, Abriouel H, Pérez Pulido R, Gálvez A. Isolation and identification of bacteria from organic foods: sensitivity to biocides and antibiotics. *Food Control* 2012;26:73–8.
- [31] Gadea R, Fernández Fuentes MÁ, Pérez Pulido R, Gálvez A, Ortega E. Effects of exposure to quaternary-ammonium-based biocides on antimicrobial susceptibility and tolerance to physical stresses in bacteria from organic foods. *Food Microbiol* 2017;63:58–71.
- [32] Poole K. Mechanisms of bacterial biocide and antibiotic resistance. *J Appl Microbiol* 2002;92:55–64.
- [33] Buffet-Bataillon S, Tattevin P, Maillard J, Bonnaure-Mallet M, Jolivet-Gougeon A. Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance in bacteria. *Future Microbiol* 2016;11:81–92.
- [34] Meradi L, Djahoudi A, Abdi A, Bouchakour M, Perrier Gros Claude J-D, Timinouni M. Résistance aux quinolones de types *qnr*, *aac(6)-Ib-cr* chez les entérobactéries isolées à Annaba en Algérie [*qnr* and *aac(6)-Ib-cr* type quinolone resistance among Enterobacteriaceae isolated in Annaba, Algeria]. *Pathol Biol* 2011;59:e73–8.
- [35] Yanat B, Machuca J, Díaz-De-Alba P, Mezhoud H, Touati A, Pascual Á, et al. Characterization of plasmid-mediated quinolone resistance determinants in high-level quinolone-resistant Enterobacteriaceae isolates from the community: first report of *qnrD* gene in Algeria. *Microb Drug Resist* 2017;23:90–7.
- [36] Yang S, Clayton SR, Zechiedrich EL. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in *Escherichia coli*. *J Antimicrob Chemother* 2003;51:545–56.
- [37] Edgar R, Bibi E. MdfA, an *Escherichia coli* multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. *J Bacteriol* 1997;179:2274–80.
- [38] Fernández Fuentes MÁ, Ortega Morente E, Abriouel H, Pérez Pulido R, Gálvez A. Antimicrobial resistance determinants in antibiotic and biocide-resistant Gram-negative bacteria from organic foods. *Food Control* 2014;37:9–14.